Editas Medicine nabs rare pediatric disease tag for sickle cell candidate

Editas Medicine (EDIT +0.1%) announced FDA approval of Rare Pediatric Disease designation for EDIT-301, for the treatment of sickle cell disease and plans to file an IND application by the end of 2020.

“We know patients are counting on us, and this designation is a significant milestone for the program that highlights the serious, life-threatening manifestations of sickle cell disease.” said Cynthia Collins, CEO.

Rare Pediatric Disease Designation provides for the issuance of a rare pediatric disease priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or it can be sold to a third party.

https://seekingalpha.com/news/3608229-editas-medicine-nabs-rare-pediatric-disease-tag-for-sickle-cell-candidate